Phase I trial is designed to assess bavituximab as combination therapy along with the chemotherapeutic agent paclitaxel in metastatic HER2-negative breast cancer patients.
Bavituximab previously established tumor response and survival trends in two Phase II advanced breast cancer trials.
Peregrine clinical and regulatory affairs vice president Joseph Shan said, "Two prior bavituximab clinical trials have demonstrated impressive tumor response rates as well as very encouraging overall survival trends in patients with advanced breast cancer."
At present, the phosphatidylserine-targeting monoclonal antibody is being assessed in several oncology trials such as an indication for second-line non-small cell lung cancer.